Understanding Ozempic and Gastroparesis: Patient History and Monitoring

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health to Targeted Exposure Awareness

If you or someone you know has been taking Ozempic and is experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering about the connection to gastroparesis. Clinicians have long recognized that certain medications can slow gastric emptying, and the growing use of GLP-1 receptor agonists like Ozempic has brought renewed attention to this risk. This page reviews the patient history and clinical timeline to help you understand who may need closer monitoring.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes. Its mechanism of action includes slowing gastric emptying, which can contribute to gastrointestinal adverse effects. Among the most serious of these is gastroparesis, a condition characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical presentation of gastroparesis often includes chronic nausea and vomiting, postprandial fullness, and bloating, which can overlap with common side effects of Ozempic. Diagnosis typically involves gastric emptying scintigraphy or breath tests to confirm delayed emptying. The pharmacology of Ozempic directly implicates it in the development of gastroparesis. GLP-1 receptor agonists like semaglutide slow gastric motility as part of their therapeutic effect on postprandial glucose levels. However, this effect can become pathological, leading to symptomatic gastroparesis. In clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additionally, specific gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal adverse events, which aligns with the mechanistic pathway of delayed gastric emptying.

Mechanistic Evidence and Risk Context

The mechanistic link between Ozempic and gastroparesis is well-supported by the drug's known effects on gastric motility. GLP-1 receptors are expressed in the gastrointestinal tract, and their activation by semaglutide inhibits antral contractions and stimulates pyloric tone, leading to slowed gastric emptying. In susceptible individuals, this can progress to clinically significant gastroparesis. The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, as noted in clinical trials, but may also develop after prolonged use. The risk appears to be dose-related, with higher doses associated with increased gastrointestinal adverse reactions. Regarding risk anchors, the adequacy of warnings on Ozempic's label is a critical consideration. The prescribing information includes warnings about gastrointestinal adverse reactions, but does not specifically list gastroparesis as a distinct warning. Instead, it groups symptoms like nausea, vomiting, and diarrhea under gastrointestinal adverse reactions. The label also includes a warning for serious hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific gastroparesis warning may be a point of contention in settlement-related considerations, as patients may argue that the risks were not adequately communicated.

Legal Considerations for North Carolina Workers

For affected patients in North Carolina, settlement-related considerations must account for the statute of limitations, which typically begins to run from the date of injury or when the injury was discovered. The timeline between exposure and documented harm is crucial; patients who developed gastroparesis after starting Ozempic should document the onset of symptoms and any medical diagnoses. The evidence from clinical trials shows that gastrointestinal adverse reactions often occur during dose escalation, but the development of gastroparesis may be delayed. Patients should seek legal counsel to determine if their claims fall within the applicable statute of limitations. In summary, the evidence supports a mechanistic link between Ozempic and gastroparesis through delayed gastric emptying, with clinical trial data showing a dose-dependent increase in gastrointestinal adverse reactions. The adequacy of warnings is questionable, as the label does not specifically mention gastroparesis. Patients in North Carolina should be aware of the statute of limitations and the need to document the timeline between Ozempic use and the onset of gastroparesis symptoms.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

In North Carolina, the statute of limitations for personal injury claims is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For Ozempic-induced gastroparesis, the clock typically starts when the patient is diagnosed or when symptoms manifest. It is crucial to consult with an attorney to determine the exact deadline based on individual circumstances.

Does Ozempic's label warn about gastroparesis?

The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions such as nausea, vomiting, and diarrhea, but it does not specifically list gastroparesis as a distinct warning. This lack of specific warning may be relevant in legal claims, as patients may argue that the risks were not adequately communicated. The label does include warnings for serious hypersensitivity reactions (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.